These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34024838)

  • 1. Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses.
    Alves SS; Silva-Junior RMPD; Servilha-Menezes G; Homolak J; Šalković-Petrišić M; Garcia-Cairasco N
    J Alzheimers Dis; 2021; 82(1):71-105. PubMed ID: 34024838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The amyloid cascade hypothesis: are we poised for success or failure?
    Karran E; De Strooper B
    J Neurochem; 2016 Oct; 139 Suppl 2():237-252. PubMed ID: 27255958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?
    Mullane K; Williams M
    Biochem Pharmacol; 2013 Feb; 85(3):289-305. PubMed ID: 23178653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():359-375. PubMed ID: 30273553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Can Insulin Resistance Cause Alzheimer's Disease?
    Yoon JH; Hwang J; Son SU; Choi J; You SW; Park H; Cha SY; Maeng S
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():376-401. PubMed ID: 30273552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMPK: Potential Therapeutic Target for Alzheimer's Disease.
    Yang L; Jiang Y; Shi L; Zhong D; Li Y; Li J; Jin R
    Curr Protein Pept Sci; 2020; 21(1):66-77. PubMed ID: 31424367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-β and islet amyloid pathologies link Alzheimer's disease and type 2 diabetes in a transgenic model.
    Wijesekara N; Ahrens R; Sabale M; Wu L; Ha K; Verdile G; Fraser PE
    FASEB J; 2017 Dec; 31(12):5409-5418. PubMed ID: 28808140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.
    de la Monte SM
    Curr Alzheimer Res; 2012 Jan; 9(1):35-66. PubMed ID: 22329651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease.
    Wakabayashi T; Yamaguchi K; Matsui K; Sano T; Kubota T; Hashimoto T; Mano A; Yamada K; Matsuo Y; Kubota N; Kadowaki T; Iwatsubo T
    Mol Neurodegener; 2019 Apr; 14(1):15. PubMed ID: 30975165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin signaling: An opportunistic target to minify the risk of Alzheimer's disease.
    Pardeshi R; Bolshette N; Gadhave K; Ahire A; Ahmed S; Cassano T; Gupta VB; Lahkar M
    Psychoneuroendocrinology; 2017 Sep; 83():159-171. PubMed ID: 28624654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
    Mullane K; Williams M
    Biochem Pharmacol; 2020 Jul; 177():113945. PubMed ID: 32247851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural products as a rich source of tau-targeting drugs for Alzheimer's disease.
    Calcul L; Zhang B; Jinwal UK; Dickey CA; Baker BJ
    Future Med Chem; 2012 Sep; 4(13):1751-61. PubMed ID: 22924511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comprehensive Review of Alzheimer's Association with Related Proteins: Pathological Role and Therapeutic Significance.
    Kumar D; Sharma A; Sharma L
    Curr Neuropharmacol; 2020; 18(8):674-695. PubMed ID: 32172687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model.
    Imamura T; Yanagihara YT; Ohyagi Y; Nakamura N; Iinuma KM; Yamasaki R; Asai H; Maeda M; Murakami K; Irie K; Kira JI
    Neurobiol Dis; 2020 Apr; 137():104739. PubMed ID: 31927145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.
    Bateman RJ; Klunk WE
    Neurotherapeutics; 2008 Jul; 5(3):381-90. PubMed ID: 18625449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology.
    Kamat PK; Kalani A; Rai S; Tota SK; Kumar A; Ahmad AS
    Mol Neurobiol; 2016 Sep; 53(7):4548-62. PubMed ID: 26298663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of insulin resistance in Alzheimer's disease.
    Cai Z; Xiao M; Chang L; Yan LJ
    Metab Brain Dis; 2015 Aug; 30(4):839-51. PubMed ID: 25399337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.